Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | GALR2 | O43603 | 1/20 | 0.34 |
| ▸ | GALR1 | P47211 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.34 |
| ▸ | ITGAL | P20701 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690675 | 0.92 | SCN9A (0.38) | SCN9APGK1GALR2GALR1ITGB2 | |
| SCHEMBL10185797 | 0.89 | SCN9A (0.42) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL1690648 | 0.86 | SCN9A (0.39) | SCN9AITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL322805 | 0.83 | SCN9A (0.43) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL17293706 | 0.79 | SCN9A (0.41) | SCN9ARETCYP2C9SCN5ASCN1A | |
| SCHEMBL1690602 | 0.75 | SCN9A (0.52) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL10185423 | 0.74 | SCN9A (0.51) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL1690594 | 0.74 | SCN9A (0.50) | SCN9ACYP2C9SCN1ASCN2ASCN8A | |
| SCHEMBL1690576 | 0.72 | SCN9A (0.56) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL10147882 | 0.71 | SCN9A (0.53) | SCN9ACYP2C9SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | SCN9A 12/4885PGK1 3700/4885GALR2 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.